Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) EBIT Margin (2016 - 2026)

Heron Therapeutics filings provide 13 years of EBIT Margin readings, the most recent being 13.73% for Q1 2026.

  • On a quarterly basis, EBIT Margin fell 2183.0% to 13.73% in Q1 2026 year-over-year; TTM through Mar 2026 was 6.94%, a 453.0% decrease, with the full-year FY2025 number at 1.64%, up 635.0% from a year prior.
  • EBIT Margin hit 13.73% in Q1 2026 for Heron Therapeutics, down from 0.09% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 10.23% in Q4 2024 to a low of 268.25% in Q1 2022.
  • Median EBIT Margin over the past 5 years was 17.89% (2024), compared with a mean of 63.7%.
  • Biggest five-year swings in EBIT Margin: skyrocketed 19141bps in 2022 and later plummeted -2183bps in 2026.
  • Heron Therapeutics' EBIT Margin stood at 67.79% in 2022, then surged by 56bps to 29.85% in 2023, then skyrocketed by 134bps to 10.23% in 2024, then plummeted by -99bps to 0.09% in 2025, then crashed by -14763bps to 13.73% in 2026.
  • The last three reported values for EBIT Margin were 13.73% (Q1 2026), 0.09% (Q4 2025), and 10.71% (Q3 2025) per Business Quant data.